Supplementary Material for: Long-Term Lanreotide Treatment in Six Patients with Congenital Hyperinsulinism

<b><i>Background:</i></b> Medical treatment is a substantial therapeutic measure to achieve glycemic control and prevent hypoglycemic brain damage without surgery in patients with congenital hyperinsulinism (CHI). However, only few drugs are available and even fewer are approved as a medical therapy to maintain normal blood glucose levels. The established therapies are demanding for caregivers and complicated by different side effects such as gastrointestinal symptoms, hypertrichosis, and obesity. Therefore, it is important to develop new strategies to improve blood glucose control. <b><i>Methods:</i></b> We report the use of the very-long-acting somatostatin analogue lanreotide autogel in 6 patients with CHI over a mean duration of 40.8 months. Blood glucose levels before and after the start and dosage titration of lanreotide in these patients are compared. <b><i>Results:</i></b> In 3 of 6 patients, switching to lanreotide raised mean blood glucose levels and reduced individually as well as overall the risk for hypoglycemic episodes (odds ratio 0.38) significantly. <b><i>Conclusion:</i></b> Lanreotide autogel can be used as an alternative pharmacological treatment and may be beneficial in conservatively treated patients with CHI.

**背景**：药物治疗是先天性高胰岛素血症（congenital hyperinsulinism, CHI）患者无需手术即可实现血糖控制、预防低血糖性脑损伤的重要治疗手段。然而目前可供选择的药物寥寥无几，获批用于维持正常血糖水平的治疗药物更是屈指可数。现有标准治疗方案对护理人员要求严苛，且易引发胃肠道症状、多毛症及肥胖等多种不良反应。因此，开发改善血糖控制的新策略具有重要临床意义。

**方法**：本研究纳入6例先天性高胰岛素血症患者，报告其使用超长效生长抑素类似物兰瑞肽自凝胶（lanreotide autogel）的临床应用数据，患者接受该治疗的平均时长为40.8个月。研究对比了这些患者在起始使用兰瑞肽及调整给药剂量前后的血糖水平。

**结果**：6例患者中，有3例在转换为兰瑞肽治疗后，平均血糖水平显著升高，且个体及整体低血糖发作风险均明显降低（优势比（odds ratio）为0.38）。

**结论**：兰瑞肽自凝胶可作为先天性高胰岛素血症患者的替代药物治疗方案，对接受保守治疗的此类患者或可带来临床获益。